What the fibromyalgia propranolol study actually found

A fibromyalgia trial published last week borrowed its protocol from post traumatic stress disorder. The premise underneath it is more interesting than the result, and the result is smaller than it is going to sound.

On July 10, a team at the Université de Sherbrooke published a double blind, randomized, placebo controlled study in The Journal of Pain, the journal of the International Association for the Study of Pain (The Journal of Pain, 2026). They tested reconsolidation therapy, a treatment developed for PTSD, on people with fibromyalgia. The reasoning runs like this. Fibromyalgia is classed as nociplastic pain, meaning the pain is produced and sustained by how the central nervous system processes signals rather than by ongoing tissue damage. The researchers note that those central changes resemble what is seen in PTSD. Reconsolidation therapy leans on a property of memory: when a memory is recalled it becomes briefly unstable and has to be written back. Give propranolol, an ordinary beta blocker, inside that window, and the theory is that the memory gets written back with less of its emotional charge.

So: 24 adults with fibromyalgia, six weekly sessions in which they reactivated their pain experience through narrative description and mental imagery, followed by oral propranolol at 40 to 80 mg, or a placebo. Everyone in both groups also watched ten short videos on pain education. One detail deserves attention: participants had no comorbid PTSD. The researchers were not treating trauma that happened to arrive alongside pain. They were treating the pain itself as the threat memory.

What turned up: the propranolol group improved more than placebo on pain interference immediately after the last session (p = .032). Four weeks later that difference was gone. What did hold at follow up was emotional functioning (p = .006). Adverse events were mild and comparable across groups.

What the headline will miss

"Randomized" and "placebo controlled" carry real authority, and they are about to do some work they were not built for here. This was a feasibility study. Check the trial registry and the point is unambiguous: every registered primary outcome is a feasibility or acceptability measure, things like weekly recruitment rate, completion rate, adverse events, and whether blinding held (ClinicalTrials.gov, NCT05085782). Pain intensity and emotional functioning are listed as secondary outcomes. The study was designed to answer whether this trial can be run at all. It was not designed to answer whether the drug works.

Size matters accordingly. With 24 enrolled and four withdrawing, roughly ten people per arm reached the end. At that scale, across a set of self reported questionnaires, individual p values are fragile things. The authors say so plainly: treatment effect should be assessed in a large scale trial. They are not claiming a treatment. Whoever writes the summary might.

Then there is the detail that rarely survives into coverage. Recruitment took seven months, and 98 potential participants were screened out, 38 of them because they could not take propranolol at all. Before efficacy is even on the table, a substantial share of the people this is meant for are ineligible on the drug side. And since both groups received the pain education videos, whatever those contributed sits in both columns.

Read honestly, the durable signal here was not pain. It was emotional functioning. The pain interference benefit did not survive four weeks. That is worth saying flatly, because "faded by follow up" is the most commonly omitted phrase in health reporting.

None of which makes the study uninteresting. It makes the premise the news. A serious group, publishing in the pain field's journal of record, built a trial on the proposition that fibromyalgia pain behaves like a threat memory the nervous system keeps rehearsing, in people carrying no trauma diagnosis at all. Whether propranolol is the right lever is a question only a larger trial will settle. The framing underneath it keeps accumulating support: in fibromyalgia and widespread sensitivity, much of the work is being done by the system's own processing.

The part I recognize

I teach the Feldenkrais Method®, and what I see in clients living with widespread sensitivity is rarely a body that cannot move. It is a body braced against movement it expects to hurt, where the bracing has become its own pattern, rehearsed so often that it runs without being asked. You haven't lost movement. You've lost trust that movement will help.

If pain is a pattern the nervous system keeps writing back, then what gets written back matters. Let me be careful here. I am not claiming that Feldenkrais does what propranolol was tested to do. Nobody has shown that, and this study says nothing about it. But the two share a starting assumption. Awareness Through Movement®, the guided lessons of the method, is slow, attentive movement done only where it feels easy, pleasant, and comfortable. Practised that way, it is a repeated experience of moving without threat. Whether that touches anything at the level of memory reconsolidation is not mine to assert. What I can say is that the trial's premise and the daily experience of people with fibromyalgia are pointing in the same direction.

If you meet this story in a headline: it is early, it is small, and it is not available to you as a treatment. It is a signal about where research is looking, and the question of what to take belongs with your physician. Gentle movement of this kind sits alongside clinical care and does not replace it. Among the movement methods people practise on their own, yoga, tai chi, qigong, and the Feldenkrais based work I do, the honest framing is different mechanisms, each with its own strengths, rather than a ranking with a winner.

Whatever a larger trial eventually concludes about propranolol, the part that is already yours is what happens between appointments. That is where a format like the Feldy online movement program fits, in short gentle lessons kept low intensity on purpose, on the days no one is watching. Do less, gain more is not a slogan about lowering your expectations. For a system that has learned to expect pain, less is frequently what it can accept as evidence.